Pharma BD Deal Intelligence
Celgene and Juno announce 10-year collaboration for CAR-T immunotherapies with $1B total investment.
Celgene to pay $1 billion for decade-long partnership with Juno Therapeutics to develop immunotherapies for cancer and autoimmune diseases.
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Celgene and Juno Therapeutics entered a global collaboration for CAR-T and TCR cell therapies. Celgene paid $150M upfront plus $850M in equity investment, with up to $1B in milestones. Celgene gained options to co-develop/co-commercialize candidates including liso-cel (Breyanzi). Celgene subsequently acquired Juno for $9B in January 2018, and BMS acquired Celgene in 2019 inheriting all programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Bristol Myers Squibb (this deal) | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol Myers Squibb | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2015 deals · Celgene Corporation deals · Gene Therapy deals